Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

July 31, 2011

Conditions
Cervical Cancer
Interventions
BIOLOGICAL

cetuximab

DRUG

cisplatin

Trial Locations (18)

39216

University of Mississippi Cancer Clinic, Jackson

44109

MetroHealth Cancer Care Center at MetroHealth Medical Center, Cleveland

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

70121

Ochsner Cancer Institute at Ochsner Clinic Foundation, New Orleans

71101

Christus Schumpert Cancer Treatment Center, Shreveport

73104

Oklahoma University Cancer Institute, Oklahoma City

74104

Cancer Care Associates - Midtown Tulsa, Tulsa

91505

Providence Saint Joseph Medical Center - Burbank, Burbank

90089-9181

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles

31403-3089

Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center, Savannah

46202-5289

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

66160-7357

Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City

08043

Fox Chase Virtua Health Cancer Program at Virtua West Jersey, Voorhees Township

27157-1096

Wake Forest University Comprehensive Cancer Center, Winston-Salem

19111-2497

Fox Chase Cancer Center - Philadelphia, Philadelphia

19612-6052

McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center, Reading

77555-0361

University of Texas Medical Branch, Galveston

77030-4009

M. D. Anderson Cancer Center at University of Texas, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Gynecologic Oncology Group

NETWORK